|
Dr. Ulrich Keilholz graduated from the
University of Heidelberg Medical School in 1983 and trained in Internal
Medicine and Hematology/Oncology at the Department of Internal Medicine, University of Heidelberg. Subsequently, he continued
to work as attending physician in the same department; however, which included
a guest visit to the NIH Surgery branch in 1987. This then laid the basis for
the inauguration of the Tumor Immunology Group, which he directed in Heidelberg.
In 1997 he was appointed Professor of
Medicine and Vice Chair of the Department of Hematology, Oncology and
Transfusion Medicine at the University Hospital Benjamin Franklin, Free
University Berlin,
(now part of the Charité University Hospital System in Berlin (CBF)). In
addition, he Chairs the unit for Interdisciplinary Medical Tumor Therapy of the
Charité, CBF. The translational research areas include research in tumor
immunology and tumor biology, in addition to his clinical research program in
medical oncology with emphasis on targeted therapies. His current research
interest focuses mainly on development of tumor vaccines for a variety of
cancer histologies, and on mechanisms of tumor metastasis.
Dr. Ulrich Keilholz is a member of all major
international clinical oncology and hematology societies and is very active in
the Deutsche Krebsgesellschaft and the European Organization for Research and
Treatment of Cancer (EORTC) (early and late phase) clinical trials and
translational research projects. He serves on the editorial board of numerous journals,
including the Journal of Clinical Oncology and Deutsche Ärzteblatt.
|
